Macleods Pharmaceuticals recalled lot BLM715A of losartan combination tablets 100mg/25mg because of trace amounts of a potential cancer-causing impurity.
The U.S. Food and Drug Administration has announced another recall of a popular blood pressure medication. This time, Macleods Pharmaceuticals recalled a single batch of losartan after discovering trace amounts of a potential cancer-causing impurity.
The affected batch number BLM715A of losartan potassium/hydrochlorothiazide combination tablets 100mg/25mg, 90-count bottles have an expiration date of July 2019.
Patients should continue taking their medication until a pharmacist replaces the drugs or provides another treatment.
“Those with high blood pressure face greater risk of illness by not taking their medication than any harm that could come from these trace impurities,” said Ibrahim Fahsah, M.D., cardiologist with Norton Heart Specialists.
Norton Heart & Vascular Institute
Learn your links to heart disease. Learn more about how each impacts your heart health and what you can do to lower your risk of heart disease.
The impurity is N-nitrosodiethylamine (NDEA), which occurs naturally in certain foods. It is also found in drinking water, air pollution and industrial processes. The batch of Losartan contains more NDEA than the FDA has determined as an acceptable daily intake level.
There have been more than a dozen recalls of various high blood pressure drugs in recent months, including valsartan, irbesartan and losartan for trace amounts of NDEA or another probable carcinogen, NDMA.